<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891172</url>
  </required_header>
  <id_info>
    <org_study_id>C-IVIG-02</org_study_id>
    <nct_id>NCT04891172</nct_id>
  </id_info>
  <brief_title>Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients</brief_title>
  <official_title>Phase II/III Clinical Trial Study to Evaluate Efficacy and Safety of Anti COVID 19 Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dow University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Higher Education Commission (Pakistan)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dow University of Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe ill Patients will be enrolled in the study (n=310) after duly filled consent forms.&#xD;
      Recipients will be divided into 2 group, each group contain 155 patients to compare Safety&#xD;
      and efficacy of patients in Clinical Trial phase II/III. One Group will receive 0.15g/kg&#xD;
      single dose of anti COVID 19 intravenously immunoglobulin (C-IVIG) develop from convalescent&#xD;
      plasma of recovered patients from COVID 19, along with Standard of care. The Comparator group&#xD;
      will only receive standard of Care&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research team at Dow University of Health Sciences has purified immunoglobulin (both SARS-CoV&#xD;
      2 antibodies and existing antibodies) from convalescent plasma of COVID19 individuals and&#xD;
      pooled to prepared IVIG formulation to treat severe and critically ill COVID-19 patients.&#xD;
      Phase I/II trial was completed and shown potential safety and efficacy of the drug Anti COVID&#xD;
      19 intravenous immunoglobulin (C-IVIG) in severe and critical patient of COVID 19.&#xD;
&#xD;
      This trial aim is to investigate the safety and efficacy of passive immunization in severe&#xD;
      COVID 19 patients in phase II/III. The trial will be randomized, single-blinded, superiority&#xD;
      trial, through parallel-group design. The participant will be either to receive C-IVIG with&#xD;
      Standard of care or Placebo with Standard of care. The study will be consist of 310&#xD;
      participant in which 155 will receive single dose of C-IVIG (0.15g/kg) with standard of care&#xD;
      and 155 will receive placebo with standard of care. Standard of care is standard hospital&#xD;
      care which includes airway support, anti-viral medication, antibiotics, fluid resuscitation,&#xD;
      hemodynamic support, steroids, painkillers, and anti-pyretic.&#xD;
&#xD;
      Randomized test patients will receive single dose of C-IVIG in following two dosage groups:&#xD;
&#xD;
      Group 1 (Test): Severe COVID-19 patients: Single dose of 0.15g/Kg with standard hospital care&#xD;
&#xD;
      Group 2 (Comparator): Severe COVID-19 patients: placebo with standard hospital care only&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28 day Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>All cause mortality of participants will be monitored for 28 days to asses the safety and efficacy of C-IVIG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immediate and serious adverse event during hospital Stay</measure>
    <time_frame>28</time_frame>
    <description>Immediate adverse event (within 24 hours) and serious adverse event (throughout the hospital stay) which will be observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status of follow-up days according to 7-Catergory Ordinal Scale</measure>
    <time_frame>28 days</time_frame>
    <description>Clinical Status of follow-up days according to 7-Catergory Ordinal Scale&#xD;
Not hospitalized and no limitations of activities&#xD;
Not hospitalized, with limitation of activities, home oxygen requirement, or both&#xD;
Hospitalized, not requiring supplemental oxygen&#xD;
Hospitalized, requiring any supplemental oxygen&#xD;
Hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices&#xD;
Hospitalized, receiving invasive mechanical ventilation&#xD;
Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in C-Reactive Protein (CRP) levels</measure>
    <time_frame>3 Days</time_frame>
    <description>Change in C-Reactive protein (CRP) levels form enrollment (baseline) till 3 days followup to monitor inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in interleukin 6 (IL-6)</measure>
    <time_frame>3 days</time_frame>
    <description>Change in IL-6 levels form enrollment (baseline) till 3 days followup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in anti-SARS-CoV-2 antibody levels</measure>
    <time_frame>3 days</time_frame>
    <description>Change in IL-6 levels form enrollment (baseline) till 3 days followup by quantitive method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Horowitz idex</measure>
    <time_frame>28 days</time_frame>
    <description>The Horowitz index is a ratio used to assess lung function in patients during Hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in radiological findings</measure>
    <time_frame>28</time_frame>
    <description>Change in any radiological after receive single Dose of C-IVIG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The Control group will be receive Standard of care only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-IVIG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will receive the single dose of C-IVIG (0.15g/kg) with Standard of Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)</intervention_name>
    <description>Intervention arm will receive single dose of 0.15g/kg C-IVIG. This will be infused within period of 16 hours intravenously. Additionally, all participants will receive same standard care.&#xD;
Standard Care as per hospital protocol, which may include:&#xD;
Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics, anti coagulant</description>
    <arm_group_label>C-IVIG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Above 18 years of age&#xD;
&#xD;
          2. Have positive COVID PCR on nasopharyngeal and/or oropharyngeal swabs&#xD;
&#xD;
          3. classified as severe* COVID-19 according to WHO guideline&#xD;
&#xD;
          4. Consent given by the patient or first degree relative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Critical COVID-19 patients&#xD;
&#xD;
          2. Pregnant females&#xD;
&#xD;
          3. Previous allergic reaction to immunoglobulin treatment&#xD;
&#xD;
          4. Patient given immunomodulatory drug (e.g. tociluzumab)&#xD;
&#xD;
          5. Patient requiring 2 inotropic agents to maintain blood pressures&#xD;
&#xD;
          6. Known case of any autoimmune disorder&#xD;
&#xD;
          7. Chronic kidney disease&#xD;
&#xD;
          8. Known case of thromboembolic disorder&#xD;
&#xD;
          9. Aseptic meningitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaukat Ali, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dow University of Health Sciences, Principal Dow College of Biotechnology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaukat Ali, PhD</last_name>
    <phone>+92-3363010185</phone>
    <email>ali.shaukat@duhs.edu.pk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Muneeba Sayeed, FCPS</last_name>
    <phone>+92-3002167826</phone>
    <email>muneeba.sayeed@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dow University of Health Sciences</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>74200</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. Mohammed Saeed Quraishy, FRCS, FCPS</last_name>
      <phone>+91-03008240234</phone>
      <email>vc@duhs.edu.pk</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Shaukat Ali, PhD</last_name>
      <phone>+91-03363010185</phone>
      <email>ali.shaukat@duhs.edu.pk</email>
    </contact_backup>
    <investigator>
      <last_name>Prof. Dr. Mohammed Saeed Quraishy, FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Shaukat Ali, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Shobha Luxmi, FCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Farah Farhan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mr. Abdul Samad Khan, M.Phil</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ms. Fatima Anjum, M.Sc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Sheikh Muhammad Muhaymin, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mr. Mir Rashid Ali, M.Sc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mr. Syed Muneeb Uddin, M.Sc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ms. Ayesha Ali, M.Sc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mr. Elisha Shalim, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mr. Mujtaba Khan, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Muneeba Sayeed, FCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ms. Tehreem Mushtaq, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mr. Faisal shahab, M.Sc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Ali S, Luxmi S, Anjum F, Muhaymin SM, Uddin SM, Ali A, Ali MR, Tauheed S, Khan M, Bajwa M, Baig SU, Shalim E, Ahmed I, Khan AS, Quraishy S. Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Nov 2;21(1):905. doi: 10.1186/s13063-020-04839-5.</citation>
    <PMID>33138867</PMID>
  </reference>
  <reference>
    <citation>Ali S, Uddin SM, Ali A, Anjum F, Ali R, Shalim E, Khan M, Ahmed I, M Muhaymin S, Bukhari U, Luxmi S, Khan AS, Quraishy S. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma. Immunotherapy. 2021 Apr;13(5):397-407. doi: 10.2217/imt-2020-0263. Epub 2021 Feb 9.</citation>
    <PMID>33557591</PMID>
  </reference>
  <reference>
    <citation>Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, Yang L, Fu S, Wang R. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.03.044. Epub 2020 Apr 10.</citation>
    <PMID>32283154</PMID>
  </reference>
  <reference>
    <citation>Chai KL, Valk SJ, Piechotta V, Kimber C, Monsef I, Doree C, Wood EM, Lamikanra AA, Roberts DJ, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020 Oct 12;10:CD013600. doi: 10.1002/14651858.CD013600.pub3. Update in: Cochrane Database Syst Rev. 2021 May 20;5:CD013600.</citation>
    <PMID>33044747</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19 (Corona Virus Disease-2019)</keyword>
  <keyword>SARS-CoV-2 (Severe Acute respiratory syndrome Coronavirus 2)</keyword>
  <keyword>Passive immunization</keyword>
  <keyword>Intravenous Immunoglobulin (IVIG)</keyword>
  <keyword>Pooled Convalescent Plasma</keyword>
  <keyword>Severe ill COVID-19 patients</keyword>
  <keyword>Antibody</keyword>
  <keyword>Anti COVID 19 Antibodies</keyword>
  <keyword>Anti SARS CoV 2 Antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 15, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT04891172/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

